Ted Monohon

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Ted Monohon

Earlier roles on record: Chief Accounting Officer at Quince Therapeutics, Inc. (QNCX) until March 16, 2023. Quince Therapeutics, Inc. reported in an 8-K filed March 3, 2023 that Ted Monohon resigned as Chief Accounting Officer and Vice President of Finance, including as the principal financial officer and principal accounting of, effective March 16, 2023.

“On March 1, 2023, Ted Monohon informed Quince Therapeutics, Inc. (the "Company") of his intention to resign from his position as the Chief Accounting Officer and Vice President of Finance, including as the principal financial officer and principal accounting officer, effective as of March 16, 2023.”

Quince Therapeutics, Inc. Form 8-K, filed March 3, 2023 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Research with Equibles

Turn this profile into a cited research brief

Start with a question tailored to the filings and events on this page, or connect Equibles financial data to ChatGPT or Claude.

Suggested question: “Summarize Ted Monohon's recent executive appointments or departures and cite the source filings.”

Use in your AI

Affiliation history

Recorded current and former roles; source labels appear when available.

Quince Therapeutics, Inc. (QNCX)
Chief Accounting Officer

SEC 8-K

2021-02-10–2023-03-16

Company network

Recorded roles and call appearances connecting this person to public companies.

Quince Therapeutics, Inc.

QNCX

Chief Accounting Officer

2021-02-10–2023-03-16

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.

Executive change Resigned: Chief Accounting Officer and Vice President of Finance, including as the principal financial officer and principal accounting of Quince Therapeutics, Inc. (QNCX)
2023-03-16